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Abstract
The RNA-binding protein Hu antigen R (HuR) binds to AU-rich elements (ARE) in the 3’-
untranslated region (UTR) of target mRNAs. The HuR-ARE interactions stabilize many
oncogenic mRNAs that play important roles in tumorigenesis. Thus, small molecules that
interfere with the HuR-ARE interaction could potentially inhibit cancer cell growth and pro-
gression. Using a fluorescence polarization (FP) competition assay, we identified the com-
pound azaphilone-9 (AZA-9) derived from the fungal natural product asperbenzaldehyde,
binds to HuR and inhibits HuR-ARE interaction (IC50 ~1.2 μM). Results from surface plas-
mon resonance (SPR) verified the direct binding of AZA-9 to HuR. NMR methods mapped
the RNA-binding interface of HuR and identified the involvement of critical RNA-binding resi-
dues in binding of AZA-9. Computational docking was then used to propose a likely binding
site for AZA-9 in the RNA-binding cleft of HuR. Our results show that AZA-9 blocks key
RNA-binding residues of HuR and disrupts HuR-RNA interactions in vitro. This knowledge is
needed in developing more potent AZA-9 derivatives that could lead to new cancer therapy.
Introduction
The limited lifetime and subsequent decay of messenger RNA (mRNA) is an important mech-
anism for posttranscriptional regulation of gene expression. In mammalian cells, mRNA
decay is dependent on both cis elements located in the RNA and trans acting regulatory factors
such as RNA-binding proteins. AU-rich elements (ARE) in 3’-untranslated region (UTR) of
mRNAs are common cis elements that promote rapid degradation of mRNAs [1, 2]. Specific
RNA-binding proteins can bind to AREs and either accelerate decay or protect mRNA from
degradation [1–4].
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The RNA-binding protein Hu antigen R (HuR), a ubiquitous member of the ELAV/Hu
protein family, binds and stabilizes ARE-containing mRNAs that encode oncoproteins, cyto-
kines, growth factors and transcription factors [3–7]. HuR is a multi-domain protein contain-
ing three RNA-recognition motifs, RRM1, RRM2, and RRM3, with each RRM comprising
of about 80 amino acids. High affinity binding of HuR to ARE of mRNA is accomplished via
its two tandem N-terminal RRM, RRM1 and RRM2 that are separated by a 7-residue inter-
domain linker [8]. The third RRM of HuR, RRM3, along with the basic hinge region that
connects RRM2 with RRM3 mediate cooperative assembly of HuR oligomers on RNA [9].
Although HuR is predominantly nuclear, the protein rapidly translocates to the cytoplasm in
response to stimuli mediated by a nucleo-cytoplasmic shuttling sequence located in the hinge
region [10]. Further, HuR is phosphorylated, ubiquitinylated, and methylated; and these post-
translational modifications of HuR affect its RNA-binding, subcellular localization, and stabil-
ity (reviewed in [11]).
HuR is overexpressed in a wide variety of cancers, including colon, ovarian, brain, breast,
cervical, and pancreas [7, 12–14]. HuR promotes tumorigenesis by binding to cancer-associ-
ated ARE-containing mRNAs that encode proteins implicated in tumor cell proliferation,
cell survival, angiogenesis, invasion, and metastasis [7, 15–17]. HuR binds and stabilizes the
AREs of the oncogene Musashi1 (Msi1) and anti-apoptotic proteins, Bcl2 and XIAP, thereby
up-regulating their expression and activating the Wnt/Notch signaling pathway and inhibiting
apoptosis [15, 18, 19]. Disrupting HuR-ARE interaction is thus an attractive strategy in devel-
oping new cancer therapeutics [16, 20–22]; and small molecule inhibitors of HuR have been
reported [16, 23–25].
We have previously reported screening of ~6000 small molecule compounds for HuR
inhibitors using a fluorescence polarization assay [22]. To expand the known chemical space
of HuR inhibitors [16, 22–25], we report here that azaphilones inhibit HuR-RNA interaction.
Azaphilones are derived from the fungal natural product asperbenzaldeyde [26, 27]). We char-
acterized the HuR-binding of the most potent azaphilone derivative, azaphilone-9 (AZA-9), by
fluorescence polarization (FP), surface plasmon resonance (SPR), nuclear magnetic resonance
(NMR), and computational modeling. AZA-9 disrupts HuR-RNA interaction by competitive
binding in the RNA-binding cleft of HuR.
Materials and methods
Protein expression and purification
The protein expression and purification of full length HuR (326 residues) and HuR RRM1/2
(residues 18–186) have been described [22]. For NMR studies, in addition to 15N-labeling, we
also used ILV-labeling, where the Isoleucine Cδ1 and the geminal Leucine Cδ and Valine Cγ
methyl groups are 13C-labeled by growing E. coli in M9 minimal media supplied with 13C
alpha keto acids. His6-tagged HuR RRM1/2 simultaneously labeled with
15N and ILV was pre-
pared by expression in E. coli BL21 (DE3) grown in 1 liter of M9 minimal media supplemented
with 1 g of 15N-ammonium chloride and 3 g of glucose at 37˚C. At OD600 ~0.4, the growth
medium was supplied with 60 mg of 2-ketobutyric acid-4-13C (Sigma #571342) to label the
13Cδ1 methyl group of isoleucine and 100 mg of 2-keto-3-(methyl-13C)-butyric acid-4-13C
(Sigma #571334) to label the two leucine 13Cδ and the two valine 13Cγ methyl groups [28].
Approximately 1 hour later (at OD600 of ~0.8), the culture was induced with 0.7 mM isopro-
pyl-β-D-thiogalactopyranoside (IPTG), and cell growth was continued overnight in a 15˚C
shaker incubator to a final OD600 ~2.5. Cells were harvested by centrifugation (2,400 × g, 10
min), resuspended in binding buffer (30 mL; 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 5 mM
imidazole), and lysed by sonication in the presence of 0.1 mM phenylmethanesulfonylfluoride
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(PMSF). Cellular debris was removed by centrifugation (13,900 × g, 10 min), and 600 μL of 5%
(v/v) polyethyleneimine was added to the supernatant to precipitate the nucleic acids. Follow-
ing centrifugation (13,900 × g, 10 min), the supernatant was loaded into a 5 mL Ni2+ column,
washed with binding buffer and the His6-tagged HuR RRM1/2 was eluted with elution buffer
(500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole). The HuR RRM1/2 construct
used herein retained an N-terminal His6-tag. Purified protein was dialyzed in buffer (100 mM
NaCl, 10 mM NaPO4 pH 6.8) and concentrated using Amicon Ultra 3K centrifugal filter
(Millipore). Protein concentration was determined by A280.
ILV assignment
Mutagenesis was used to assign the ILV resonances by introducing conservative mutations
(I!L, L!I, and V!I) in HuR RRM1/2. The QuikChange kit (Stratagene) was used to in-
troduce site-directed mutants and mutations were verified by DNA sequencing. Proteins
obtained from cell growth in 200 mL of M9 minimal media supplied with the appropriate 13C-
alpha keto acid was enough to obtain 2D 1H,13C HSQC to assign the ILV peaks of the 12 iso-
leucine and L39, L61, V66, and L138 residues of HuR RRM1/2.
Chemicals and reagents
Synthetic RNA oligos were from Dharmacon. For FP assay, fluorescein-tagged AREMsi1 oligo
derived from the 3’-UTR of Musashi RNA-binding protein 1 (Msi1) with the sequence 5’-
GCUUUUAUUUAUUUUG-3’and 11-mer AREc-fos RNA oligo (5’-AUUUUUAUUUU-3’) iden-
tical to the c-fos RNA sequence used in the crystal structure of HuR-RNA complex [8] were
used. For NMR studies, unmodified 11-mer AREc-fos RNA oligo [8] was used. Prior to the
addition of RNA to the protein, the RNA was heated at 95˚C for 5 min followed by immediate
cooling on ice for 5 min. The azaphilone derivatives used herein were obtained by semisyn-
thetic diversification of asperbenzaldehyde, which was purified from a strain of Aspergillus
nidulans that was engineered to overproduce this compound as described elsewhere [26, 27].
Compounds were dissolved in dimethyl sulfoxide (DMSO) to form 10 mM stock solutions; for
NMR studies, deuterated dimethyl sulfoxide (d6-DMSO) was used.
Biochemical assays
FP competition assay for screening and hit validation were carried out as reported previously
[22]. Briefly, compounds at increasing doses were added to plate wells prior to the addition of
pre-formed protein-AREMsi1 or protein-AREc-fos complex. To form HuR-ARE complex, 10
nM full length HuR and 2 nM Msi1 oligo or c-fos oligo were used. To form HuR RRM1/2-
AREc-fos complex, 50 nM HuR RRM1/2 and 2 nM c-fos oligo were used. Measurements were
taken using a BioTek Synergy H4 hybrid plate reader (Biotek, Winooski, VT) after incubating
for 2 hours at room temperature. IC50, the drug concentration causing 50% inhibition, was cal-
culated by sigmoid fitting of the dose response curve using GraphPad Prism 5.0. Percent inhi-
bition was calculated by comparing to the DMSO (0% inhibition) and labeled free RNA only
(100% inhibition) controls.
Surface plasmon resonance (SPR) datasets were acquired using a BIACORE 3000 (GE
Healthcare) at 20˚C as described [22]. Briefly, HuR was immobilized into a CM5 chip by
amine-coupling chemistry and AZA-9 dissolved in buffer (20 mM HEPES pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.05% p20 (v/v), 5% DMSO (v/v)) was injected into the flow cell at a flow
rate of 60 μL/min. The mixtures complexes were allowed to associate for 400 sec and dissociate
for 160 sec. SPR sensorgrams were generated using Scrubber2 (BioLogic Software, Australia).
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NMR spectroscopy
Proteins for NMR were dissolved in NMR buffer (100 mM NaCl, 10 mM NaPO4 pH 6.8, 10%
D2O).
15N NMR data were acquired using Bruker Avance 800 MHz spectrometer with a TCI
cryoprobe. ILV 13C NMR data were acquired using on a Bruker Avance III 600 MHz spec-
trometer. NMR data were acquired at 25˚C, processed using NMRPipe [29] and analyzed
using NMRView [30]. For 15N and ILV chemical shift mapping, 80 μM 15N/ILV-labeled HuR
RRM1/2 was titrated with unlabeled AREc-fos RNA at increasing molar ratios of 1:0, 1:0.5, 1:1,
and 1:1.7. AZA-9 was titrated at 1:1 and 1:2 molar ratios into 50 μM 15N/ ILV-labeled HuR
RRM1/2 in NMR buffer with 10% d6-DMSO. Higher protein concentrations or higher molar
ratios of AZA-9 resulted in sample precipitation. The 15N titrations were monitored by acquir-
ing 2D 1H-15N TROSY spectra, and the ILV titrations were monitored by acquiring 2D
1H-13C HSQC spectra. The published backbone amide assignments of HuR RRM1/2 (BMRB
entry 26628) [20] and the ILV assignments made herein were used in the NMR analysis.
Computational modeling
A docked model of how AZA-9 may bind to HuR RRM1/2 was built starting from the crystal
structure of HuR RRM1/2 in complex with RNA (PDB 4ED5) [8]. FRED (version 3.0.1) from
OpenEye Software was used for molecular docking [31]. For each of the biological units present
in PDB 4ED5, the RNA was removed and a receptor was built using APOPDB2RECEPTOR
(OpenEye Scientific Software, Santa Fe, NM). Conformers of AZA-9 were generated with
OMEGA (version 2.5.1.4) [32] using the default parameters and docked into each of the prepared
receptors using FRED at the “Standard” docking resolution. Full-atom minimization of the
model with the best score based on the Chemgauss4 scoring function was then carried out using
ROSETTA [33] using the Talaris2014 scoring function with the pwSHO solvation model [34].
Results
Protein expression and purification of HuR and HuR RRM1/2
Full length HuR (326 residues) and a shorter HuR construct consisting only of the two tandem
RRM1 and RRM2 (HuR RRM1/2; residues 18–186) were overexpressed in E. coli BL21 (DE3)
and purified under native conditions by Ni2+-affinity chromatography (S1 Fig). Typically, ~28
mg of pure unlabeled or 15N/ILV-labeled recombinant HuR RRM1/2 protein was obtained per
liter of LB or M9 minimal medium. The HuR RRM1/2 was soluble in 100 mM NaCl, 10 mM
sodium phosphate pH 6.8 buffer at a concentration of ~6 mg/mL (~0.27 mM protein concen-
tration), beyond which, it precipitated at higher concentrations.
Identification of AZA-9 as an inhibitor of HuR-RNA interaction
A FP-based high throughput screen on HuR and a 16-mer AREMsi1 RNA oligomer from the 3’-
UTR of Musashi1 (Msi1) mRNA previously identified novel small molecule inhibitors of HuR-
ARE interaction [22]. This FP assay [22] was used here to screen ~2000 compounds to identify
more potent inhibitors of HuR-ARE interaction. The library contained 1673 compounds from
the National Cancer Institute (Diversity Set II, Natural Products Set, and Approved Oncology
Drugs Set) plus 291 in-house compounds. The screening identified a class of fungal natural
products, azaphilones, as possible hits (S2 Fig). Azaphilones exhibit diverse biological effects,
including cytotoxic, anti-inflammatory, anti-proliferative, and anti-tumorigenic activities [26,
35, 36]. The possible hits were azaphilones, which were compounds derived semi-synthetically
from a fungal natural product, asperbenzaldehyde [22]. Multi-dose effect was determined to
verify the inhibition of HuR-ARE interaction. All azaphilone derivatives tested (AZA-7 through
AZA9 inhibits HuR-RNA interaction
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AZA-14) except the negative control AZA-15, showed dose-dependent inhibition of HuR-AR-
EMsi1 interaction (S2 Fig). AZA-9 with a IC50 value of 1.1 μM (n = 3) was the most potent com-
pound among the nine azaphilone derivatives and thus was chosen for further characterization.
To confirm that the inhibition of HuR-ARE interaction is not mRNA specific and to further
characterize the interaction between AZA-9 and HuR by NMR methods, we used another HuR
target ARE, AREc-fos, which is identical to the c-fos RNA sequence used in the crystal structure
of HuR-RNA complex [8]. Similar to AREMsi1, AREc-fos shows tight binding to full length HuR
and a smaller fragment, HuR RRM1/2, with a Kd of 3.3 nM and 22.2 nM, respectively (Fig 1A
Fig 1. AZA-9 inhibits HuR-ARE RNA interaction and binds directly to HuR. Titration of 2 nM AREc-fos and
control RNA (a 16-nt fluorescein-labeled RNA oligo with random sequence) with (A) HuR and (B) HuR RRM1/
2 (n = 3). (C) Dose-response curve of AZA-9 disrupting HuR-AREc-fos binding in FP assay using 10 nM HuR
and 2 nM fluorescein-labeled AREc-fos (n = 3). (D) Dose-response curve of AZA-9 disrupting HuR RRM1/
2-AREc-fos binding in FP assay using 50 nM HuR RRM1/2 and 2 nM fluorescein-labeled AREc-fos (n = 3). (E)
SPR sensorgrams of AZA-9 injected at increasing concentrations of 0–125 μM into a flow cell containing
immobilized HuR (n = 2). Structure of AZA-9 is shown on the right. The following were the negative controls
used–random RNA in (A) and (B); and AZA-15 in (C) and (D).
https://doi.org/10.1371/journal.pone.0175471.g001
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and 1B). The AREc-fos interaction to either full length HuR (Fig 1C) or HuR RRM1/2 (Fig 1D)
was disrupted in a dose-dependent manner upon addition of AZA-9, with IC50 value of 1.2 μM
for full length HuR and 7.4 μM for HuR RRM1/2. SPR confirmed the direct binding of AZA-9
to HuR. Upon injections of increasing concentrations of AZA-9 on immobilized HuR, SPR sen-
sorgrams showed increased optical response in a dose-dependent manner (Fig 1E). These find-
ings indicate that AZA-9 disrupts HuR-ARE interaction through direct binding to HuR.
NMR titrations of 15N-labeled HuR RRM1/2 with AREc-fos
Full length HuR gave non-ideal NMR spectra that made further NMR characterization chal-
lenging [20]. We therefore used a smaller fragment of HuR, HuR RRM1/2, which contains the
essential domain needed for direct binding to AREc-fos. The 2D 1H-15N TROSY spectrum of
HuR RRM1/2 (Fig 2A) closely resembled the reported 2D 1H-15N HSQC spectrum, [20]
thereby allowing use of the reported backbone amide assignments of HuR RRM1/2 [20] in our
analysis. Overall, the 2D 1H-15N spectrum of HuR RRM1/2 is well dispersed with ~175 sharp,
well-resolved peaks as expected for the construct (Fig 2A). To gain insights into the interaction
of HuR RRM1/2 and RNA in solution, we used the same 11-mer c-fos RNA oligo (AREc-fos)
used in the co-crystallization of HuR RRM1/2 [8] for the NMR characterization of protein-
RNA interaction. 15N-labeled HuR RRM1/2 was titrated with increasing concentrations of
unlabeled AREc-fos at 1:0.5, 1:1, and 1:1.7 molar ratios, and the titration was monitored by
acquiring 2D 1H-15N TROSY spectra. The stepwise addition of AREc-fos induced mainly peak
broadening of specific HuR RRM1/2 resonances (Fig 2A) indicating that the interaction
occurred in intermediate exchange NMR time scale for the backbone amides. Protein-RNA
contacts have been identified in the co-crystal structure of HuR RRM1/2-AREc-fos [8]. Some
essential HuR residues identified contributing to the specific recognition of RNA substrate
through side-chain, main-chain and/or stacking interactions include residues Y26, R97, I103,
Y109, and R153 [8]. These residues showed significant peak intensity reduction during the
NMR titration (Fig 2B). To identify the amino acids involved in AREc-fos binding, we calcu-
lated the peak intensity ratio (I1:1/I1:0) for each non-overlapped peak at an HuR RRM1/2:RNA
molar ratio of 1:1 (Fig 2C). Residues with peak intensity ratio lower than average intensity
minus one standard deviation were mapped onto the co-crystal structure of the protein-RNA
complex (Fig 2E). HuR RRM1/2 residues with significant peak intensity reduction cluster
together in the β-strands, surrounding loops and linker region of RRM1/2 and form the RNA-
binding surface of RRM1/2 (Fig 2E). The RNA interaction surface determined by NMR is con-
sistent with the crystal structure of HuR-RNA complex.
Although the HuR RRM1/2 residues directly in contact with or in close proximity to the
RNA showed reduction in peak intensities as described above, several residues distant from
the RNA-binding site showed changes in peak positions in the presence of RNA (Fig 2D).
Inspection of these peaks at lower contour level revealed the appearance of a new peak at a
slightly different frequency with increasing concentrations of RNA. The original peak from the
RNA-free form of HuR RRM1/2 gradually broadens, while the new peak emerging from the
RNA-bound form progressively gains intensity with increasing amounts of RNA. HuR RRM1/
2 residues displaying such shifts were mapped onto the structure of RNA-bound HuR (Fig
2E). Because these residues are situated ~9–13 Å apart from the RNA-binding site, such per-
turbations can be most directly interpreted a result of conformational change upon RNA bind-
ing. The appearance of two peaks corresponding to HuR RRM1/2 residues distant from the
RNA-binding site in the presence of RNA is suggestive of slow conformational switching of
HuR upon RNA binding. The allosteric effects observed in solution are in agreement with
crystal structures and small-angle X-ray scattering (SAXS) analysis of RNA-free versus bound
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forms of HuR that demonstrate subtle conformational changes play a major role in formation
of a stable compact HuR RRM1/2-RNA complex [8, 37].
NMR assignment of ILV-labeled HuR RRM1/2
ILV labeling offer additional probes in NMR studies because of their high sensitivity. Similar
to the amide signals shown above, perturbations of 13C methyl peaks can be used to report
on protein ligand interactions, conformational changes, structure and dynamics [28, 38, 39].
Further, side-chain interactions are crucial for the RNA recognition of HuR and methyl-con-
taining residues such as isoleucine, leucine, and valine (ILV) occur near the RNA cleft. We
therefore used ILV-labeled HuR RRM1/2 here to probe the side-chain protein-RNA interac-
tion. His6-tagged HuR RRM1/2 contains 12 isoleucine, 15 leucine and 13 valine residues (the
His-tag contributes 1 valine and 2 leucines). The 2D 1H-13C methyl HSQC spectrum of HuR
RRM1/2 (Fig 3A) showed 12 Ile peaks (corresponding to each of the δ1 methyl group of 12 iso-
leucine) within the spectral window ~8–16 13C ppm and 28 pairs of Leu and Val peaks (corre-
sponding to the two δ1 and δ2 methyl groups of 15 leucines; and the two γ methyl groups of 13
valines) within 19–28 13C ppm range. To assign the 16 ILV residues used herein, fifteen point
mutations were introduced in HuR RRM1/2 (with isoleucine mutated to leucine; and leucine
or valine mutated into isoleucine), and the resultant protein expressed and purified under
native conditions. Comparable to the wild type construct, the mutant proteins were soluble at
~6 mg/mL in 100 mM NaCl, 10 mM sodium phosphate pH 6.8 buffer. To illustrate the assign-
ment method to assign I23 for example, comparison of the 2D 1H-13C HSQC spectrum of the
I23L point mutant that was selectively 13C-labeled at the isoleucine δ1 methyl with the spec-
trum of the wild type protein (S3A Fig), enabled the unambiguous assignment of the 13Cδ1
methyl resonance of I23. All the 12 isoleucine residues were assigned in addition to 3 leucines
(L39, L61, and L138) and a valine residue, V66 (Fig 3A). These 16 ILV probes are strategically
located and provide overall coverage of the HuR RRM1/2 structure.
Titrations of ILV-labeled HuR RRM1/2 with AREc-fos
To monitor the effect of RNA binding on ILV methyl resonances of HuR RRM1/2, 2D 1H-13C
HSQC spectra were acquired on various titration samples. Of the assigned side chain methyl
resonances, peaks corresponding to I23, I52, and L61 of RRM1, I103 of inter-domain linker
region, and I133, L138, and I152 of RRM2 disappeared from their free position and reappeared
at a different frequency in the spectrum as new peaks for the protein-RNA complex (Fig 3A).
This indicates that the side-chains of these residues either directly mediate tight RNA-binding
or are present in close proximity to the RNA and thus, experience strong perturbation in their
local chemical environment upon RNA-binding. The affected ILV residues (I23, I52, L61,
I103, I133, L138, and I152) delineate the RNA-binding cavity of HuR RRM1/2 and lie within
3–4 Å of the RNA substrate (Fig 3C).
Fig 2. NMR titrations of 15N-labeled HuR RRM1/2 with AREc-fos. (A) Overlay of four 2D 1H-15N TROSY spectra of 15N HuR RRM1/2 titrated with increasing
molar ratios of AREc-fos RNA. Representative residues showing peak broadening (dashed box) and residues displaying changes in peak positions (solid box)
are shown. (B) Representative residues displaying peak broadening upon RNA binding are shown at similar contour level at individual titration points. (C) Plot
of relative peak intensity for all non-overlapping HuR RRM1/2 resonances in the ligand bound versus free state (I1:1 /I1:0). Gray and red lines correspond to the
mean and one standard deviation from the mean (1σ), respectively. (D) Representative residues that displayed changes in peak positions are shown at similar
contour level at individual titration points. While the original peak (RNA-free form) gradually decreases in intensity, a new peak (shown by arrow) appears and
progressively gains intensity with increasing concentrations of RNA. (E) Results of NMR titrations mapped onto the co-crystal structure of HuR-AREc-fos
complex (PDB 4ED5) and colored as follows: RRM1/2 residues with peak intensity ratio (I1:1 /I1:0) lower than 1σ (red), residues with new peaks shown in D
(yellow), unassigned residues (gray), and RNA (blue).
https://doi.org/10.1371/journal.pone.0175471.g002
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Analogous to the allosteric effects observed in the backbone amide titrations (Fig 2D), sev-
eral residues, such as L39, I43, V66 of RRM1, and I110, I132, I164, I179 of RRM2, with the side
chain methyl group that are positioned ~12–18 Å from the RNA binding site also showed
changes in their chemical shift positions (Fig 3B). The original free peak disappeared and a
new peak representing the RNA-bound form of HuR appeared at a slightly different position
(Fig 3B). After 1:1 complex is reached, it was observed that the addition of RNA merely
adds to the intensity of the peak of the bound form. Residues with such perturbations are
highlighted as yellow sticks in Fig 3C. The appearance of new peaks for such distant residues in
Fig 3. NMR titrations of ILV-labeled HuR RRM1/2 with AREc-fos. (A) Overlay of five 2D 1H-13C HSQC spectra of ILV-labeled HuR RRM1/2 titrated with
increasing concentrations of AREc-fos. Assigned ILV peaks, the new peaks appearing upon complex formation (*), and some representative ILV residues
away from the RNA-binding site that showed chemical shift perturbations (boxed) are indicated. (B) The boxed peaks in A are shown at a similar contour level
at individual titration points. The new peak emerging with increasing concentrations of RNA is shown by an arrow. (C) Results of NMR titration mapped onto
the co-crystal structure of HuR-AREc-fos complex (PDB 4ED5). Protein and RNA are represented as in Fig 2. Assigned ILV residues are shown as sticks and
colored as follows: RRM1/2 residues showing new complex peaks (red) and residues with chemical shift perturbations as indicated in B (yellow).
https://doi.org/10.1371/journal.pone.0175471.g003
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the RNA-bound form confirms conformational changes upon RNA-binding. The results of
side-chain ILV methyl titrations complement backbone amide titrations and together, they
support that the ß-sheet region of HuR RRM1/2 is the RNA binding surface and RNA binding
is accompanied by conformational changes in HuR.
NMR titrations of HuR RRM1/2 with AZA-9
The interaction of AZA-9 with HuR RRM1/2 was characterized by NMR methods. Titrations
of 15N/ILV-labeled HuR RRM1/2 with AZA-9 resulted in concentration dependent reduction
in the 15N and ILV peak intensities of HuR RRM1/2 (Fig 4), indicating complex formation on
an intermediate exchange time scale. In addition to the decrease in peak intensities, the side
chain methyl groups of some HuR RRM1/2 residues, such as I103, L138 (Fig 4D), also showed
chemical shift deviations upon binding of AZA-9. Further, key RNA-binding residues, Y26,
R97, I103, Y109, and R153 (Fig 2B), exhibited significant peak broadening with increasing
doses of AZA-9 in the 15N-titrations (Fig 4B). Specifically, residue R97 in the inter-domain
linker region (whose intensity reduced by ~50% at equimolar concentration of AZA-9, Fig 4C)
has been previously reported as important for RNA binding, RNA recognition and high affin-
ity HuR-RNA complex formation [8]. Comparable to the results of the amide titrations, results
of the ILV titrations of other RNA-binding residues, such as I52, L61, I103, and L138, identi-
fied earlier (Fig 3A) also displayed significant reduction in peak intensities upon addition of
AZA-9 (Fig 4D). A plot of the peak intensity ratio (I1:1/I1:0) in the bound and free form at 1:1
molar ratio (Fig 4) revealed that the NMR resonances of the major RNA-binding residues of
HuR, including K55, G62, R97, I103, L138, and R153, were significantly perturbed by AZA-9.
Residues that were significantly perturbed during titrations were mapped on the structure of
RNA-bound HuR (Fig 4F). Complex formation with AZA-9 primarily affected a cluster of
RNA-binding residues located near the inter-domain linker region of HuR (Fig 4F). NMR
results indicate that AZA-9 interacts at the same binding pocket that HuR RRM1/2 uses to
bind its target RNA.
In silico docking of AZA-9 in the RNA cleft of HuR RRM1/2
Molecular docking studies were performed to gain further insight into the binding mode of
compound AZA-9 to HuR. Fig 5A represents the top-scoring computational model of com-
pound AZA-9 bound HuR RRM1/2 generated using FRED [31], followed by full-atom mini-
mization with ROSETTA [33]. The resulting model had a score of -304.85 Rosetta Energy
Units and an interface score (the difference between the score of the complex and the sum of
the scores of the protein and AZA-9 alone) of -14.94 Rosetta Energy Units. Several hydropho-
bic and positively charged HuR residues, such as Y26, K55, R97, and R153 line the pocket for
AZA-9 and potentially stabilize the protein-ligand complex through electrostatic, hydrogen
bond, hydrophobic, and pi-stacking interactions (Fig 5A). Consistent with the NMR-derived
binding site of AZA-9 (Fig 4F), molecular docking confirmed a possible binding mode for
compound AZA-9 in the RNA binding cleft of HuR near the inter-domain linker region (Fig
5B). Together, results of NMR titrations and molecular docking indicate that compound AZA-
9 disrupts HuR-RNA interaction by competitively binding in the RNA cleft of HuR (Fig 5).
Discussion
HuR-ARE interaction [1, 4–6] contributes to carcinogenesis by stabilizing the mRNAs of
oncogenes [7, 12, 15, 18, 19], thus, finding inhibitors of HuR-ARE interaction could contribute
to the development of new cancer therapies [20, 22]. So far, there are a limited number of
HuR inhibitors [16, 20–25] that competitively bind to HuR and directly disrupt HuR-ARE
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interactions [20–22]. Currently, the most potent HuR inhibitor known, MS-444, is a bacterial
natural product isolated from Actinomyces sp. microbial broths, and MS-444 inhibits
HuR-RNA interaction by interfering with HuR homodimerization [21]. Here, we identified a
new class of compounds, azaphilones (S2 Fig) [35, 36] and in particular, AZA-9 (Fig 1), as
novel inhibitors of HuR-ARE interaction.
Fig 4. NMR titrations of HuR RRM1/2 with AZA-9. (A) Overlay of three 2D 1H-15N TROSY spectra of 15N HuR RRM1/2 titrated with
increasing molar ratios of AZA-9. The peaks of some critical RNA-binding residues that undergo significant line broadening upon
addition of AZA-9 are shown (expanded dashed box). (B) Representative residues showing peak broadening upon titration of AZA-9
are shown at similar contour level at individual titration points. (C) Relative peak intensity plot for non-overlapping amide resonances
of HuR RRM1/2 in the ligand bound versus free state (I1:1 /I1:0). (D) Overlay of three 2D
1H-13C HSQC spectra of ILV-labeled HuR
RRM1/2 titrated with increasing molar ratios of AZA-9. Analogous to 15N-titrations, ILV methyl groups of RNA-binding residues
showed peak broadening with a few residues such as I103 and L138 also displaying chemical shift deviations (dashed box). (E)
Relative peak intensity plot for assigned ILV methyl HuR RRM1/2 resonances in the ligand bound versus free state (I1:1 /I1:0). (F)
Results of titrations mapped onto the co-crystal structure of HuR-AREc-fos complex (PDB 4ED5). Protein and RNA are shown as in
Figs 2 and 3. RRM1/2 residues with peak intensity ratio (I1:1 /I1:0) lower than 1σ are colored red and the proposed AZA-9 binding site
is shown by an arrow. Most of the AZA-9 affected residues are key RNA-binding residues. (C,E) Gray and red lines correspond to the
mean and one standard deviation from the mean (1σ), respectively.
https://doi.org/10.1371/journal.pone.0175471.g004
Fig 5. Molecular docking identifies a possible binding pocket for AZA-9 in the RNA-cleft of HuR. (A)
Computational model of AZA-9 bound to HuR RRM1/2, with protein shown in surface representation and
AZA-9 in sticks. HuR RRM1/2 residues affected in AZA-9 NMR titrations are colored red. An expanded view of
the binding pocket is shown in the right. Residues involved in AZA-9 binding are displayed as sticks, with
hydrogen bonds shown as dashed lines. (B) Surface representation of HuR RRM1/2 bound to RNA (sticks)
for comparison with the AZA-9 model. Residues affected upon RNA titrations are highlighted in red. An
expanded view of the RNA-pocket is shown in the right. Residues (Y26, K55, L61, R97, R153) perturbed by
AZA-9 in the NMR titrations are critical RNA-binding residues.
https://doi.org/10.1371/journal.pone.0175471.g005
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The azaphilones studied here are derived from the fungal secondary metabolite asperben-
zaldehyde [26, 27]. Fungi-derived natural products are excellent sources of pharmaceuticals
and many fungal secondary metabolites show anti-cancer properties that inhibit cell pro-
liferation, angiogenesis, and tumorigenesis.[35, 40, 41] The two rings of azaphilones form the
isochromene scaffold, and this scaffold is present in the previously identified methyl-benzoiso-
chromene scaffold of the chrysanthones secondary fungal metabolites isolated from another
fungus, Ascochyta chrysanthemi.[41] Chrysanthones were reported to have anti-proliferative,
anti-tumorigenic and anti-angiogenic properties, however, their specific molecular target was
not determined.[41] The presence of the isochromene scaffold plus the observed anti-cancer
properties of chrysanthones could be associated to HuR inhibition.
The tandem RRM1/2 of HuR is the minimal domain needed for binding AREs. Our results
of the backbone amide titrations showed significant peak broadening for the ARE-binding res-
idues similar to what was reported by Wang et al. [20] (Fig 2), however, we also observed addi-
tional new slow exchange peaks in the ILV titrations (Fig 3). This differing NMR exchange
behavior could be due to the direct interactions of the protein side chains with the RNA sub-
strate and their dominant role in the formation of tight HuR RRM1/2-ARE complex [8]. Addi-
tionally, we observed allosteric effects in HuR RRM1/2 upon RNA binding (Figs 2D and 3B).
Conformational changes in HuR RRM1/2 on binding the RNA substrate have been previously
reported [8, 37]. These conformational changes contribute in the formation of a stable, high-
affinity HuR RRM1/2-RNA complex. Consistent with the crystal structures and SAXS analysis
[8, 37], our NMR results identified the specific residues (such as M31, T70, R85, Q141, A163,
and G169) that are involved in the slow conformational switching in HuR RRM1/2 upon RNA
binding (Figs 2 and 3).
The crystal structures of the free and RNA-bound HuR RRM1/2 [8] suggest major struc-
tural rearrangements in the relative orientation of RRM1 with respect to RRM2 upon RNA
binding (S4 Fig). For example, RRM2 has to swing about 41 Å to reposition itself vis-à-vis
RRM1 upon RNA binding. This major conformational change in HuR RRM1/2 upon RNA
binding is not reflected in the results of our NMR titrations as well as the results of the amide
titrations of Wang et al. [20]. For such major conformational rearrangements of the two RRM
domains, one would expect major changes in the peak positions in the 15N TROSY spectra of
the free and RNA-bound HuR RRM1/2 (Fig 2). Instead, we observed essentially similar peak
positions in the 15N TROSY of free and RNA-bound HuR RRM1/2 (Fig 2), with the peak
intensities of the RNA-bound form progressively weakening upon addition of more RNA. In
the ILV-titrations (Fig 3), there were indeed new slow-exchange peaks for RRM2 isoleucine
residues (I103, I133, I152) but the rest of the isoleucines in RRM2 (I110, I164, and I179) were
essentially in similar (fast exchange) peak positions as the free form suggesting the changes in
the peak positions and intensities observed by NMR are due to RNA-binding rather than the
major conformational rearrangements of the two domains upon RNA-binding. Our NMR
results suggest that RRM1 and RRM2 are somewhat ‘pre-formed’ for RNA-binding with the
two domains already close together and poised to accept the RNA. Upon RNA-binding, the
side chains and loops of HuR RRM1/2 ‘wiggle’ to accommodate and interact with the RNA.
SAXS results suggest two populations of free HuR RRM1/2 where one population has an
extended structure (with a size of 74 Å) and another population that has a more compact struc-
ture (with a size of 56 Å) [37]. Upon RNA binding, the HuR RRM1/2 becomes even more
compact (with a size of 51 Å). This suggest that SAXS is able to trap two populations of free
HuR RRM1/2 whereas our NMR results suggest an average conformation.
Our efforts to co-crystallize AZA-9 with HuR RRM1/2 have been so far unsuccessful, thus,
we used NMR methods to characterize how AZA-9 interacts with HuR RRM1/2. Results of
NMR titrations showed that AZA-9 essentially perturbs the same HuR RRM1/2 residues
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involved in binding RNA (Fig 4). NMR titrations with AZA-9 affected specific RNA-binding
residues of HuR RRM1/2 (Fig 4). The previously identified key ARE-binding residues, includ-
ing Y26, L61, R97, I103, Y109, and R153 that make side chain, main chain and/or stacking
interactions with the ARE substrate [8] showed significant NMR perturbations upon the addi-
tion of AZA-9 (Fig 4A and 4D). In particular, R97, in the inter-domain linker region, which
showed the strongest peak intensity reduction has been identified through mutagenesis as a
critical residue required for high affinity ARE binding [8]. Results of both backbone amide
and ILV titrations indicate that AZA-9 predominantly affect a surface near the inter-domain
linker region in the RNA cleft of HuR (Fig 4F).
In agreement with the NMR-derived binding site of AZA-9, results of molecular docking
positioned AZA-9 in the ARE-binding cleft near the inter-domain linker region of HuR RRM1/
2 (Fig 5A). Computational modeling suggested that AZA-9 is well situated in the binding pocket
surrounded by several positively charged and hydrophobic residues to enable hydrophobic,
hydrogen bond, and/or electrostatic interactions. In the computational model, the long hydro-
phobic tail of AZA-9 lies adjacent to the methyl side chain of I23, and runs roughly parallel to
the aliphatic chain of R97 to promote hydrophobic interactions; the oxygen atom of the pyran
ring in AZA-9 positioned such it forms a hydrogen bond with the guanidinium group of R97;
and the ester carbonyl of AZA-9 is positioned very close to the guanidinium side chain of R153,
forming a salt bridge. The interaction of AZA-9 with R97 is particularly notable as R97 was
found by crystallography [8] to be a key residue for stable HuR-ARE complex formation. Over-
all, our results show that AZA-9 competes with target ARE for binding in the RNA cleft of HuR
RRM1/2.
There are several HuR RRM1/2 residues (S88, S100, T118, S158, and K182) that are in-
volved in the phosphorylation and ubiquitinylation of HuR, and these posttranslational modi-
fications affect the RNA-binding, nucleo-cytoplasmic shuttling, and protein stability of HuR
([11]). Of these residues, S100 is closest in distance, within 5Å, to the predicted AZA-9 binding
site, and phosphorylation of S100 could be affected by AZA-9 binding. The other residues
(S88, T118, S158, and K182) are too far away from the proposed AZA-9 binding site, and are
not expected to make direct contact with AZA-9. The effect on the posttranslational sites
should be explored for the second-generation inhibitors designed on the AZA-9 scaffold that
show in vivo potency.
Our results indicate that the binding of AZA-9 to HuR is weak, occurring at about micro-
molar range (Fig 1). This weak binding suggests that AZA-9 may not be specific to HuR, and
indeed, our unpublished data indicate that AZA-9 also binds to another RRM-containing pro-
tein, Musashi-1 (Msi1). Musashi-1 contains two RRMs, which share on average about 26%
sequence identity and 41% sequence similarity with HuR RRM1/2. Nevertheless, our NMR
and modeling results (Figs 4 and 5) showing how AZA-9 binds to the RNA-binding pocket of
HuR RRM1/2 point the direction in designing improved versions of AZA-9 that could yield
tighter-binding compounds that are more specific to HuR, and yield more potent inhibitors of
HuR, that can be used for developing new anticancer therapies.
To summarize, azaphilones, and in particular, AZA-9, which are derived from fungal natu-
ral products, bind to the HuR RNA-binding domain, RRM1/2. Binding of AZA-9 to HuR dis-
rupted HuR-RNA interaction. SPR, NMR and molecular docking confirmed that AZA-9
inhibited HuR-RNA interaction by competing directly for the RNA-binding site in HuR.
Supporting information
S1 Fig. Protein gel of purified full length HuR and the HuR RRM1/2. Coomassie stained
SDS-PAGE of purified recombinant full length HuR (FL HuR, 36 kDa) and the RRM1/2
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fragment (24 kDa). Lanes were loaded with low and high amounts of purified proteins.
(TIF)
S2 Fig. Azaphilones inhibit HuR-RNA interaction. (A) Structures of azaphilone compounds
tested in the inhibition assay. (B) Dose-response curves of azaphilones disrupting HuR-AR-
EMsi1 binding in FP assay using 10 nM HuR and 2 nM fluorescein-labeled AREMsi1 RNA. Data
are representative of three independent experiments. AZA-15 does not inhibit HuR- AREMsi1
interaction and serves as negative control; all other azaphilone derivatives show dose-depen-
dent inhibition of HuR-AREMsi1 interaction.
(TIF)
S3 Fig. ILV assignments of HuR RRM1/2 by mutagenesis. 2D 1H-13C HSQC spectra for
HuR RRM1/2 mutants (red) overlaid with the wild type spectra (black). (A-K) A single miss-
ing 13Cδ1 methyl peak for Ile; and (L) two 13Cδ1 and 13Cδ2 methyl peaks for Leu correspond-
ing to the mutated residue are indicated.
(TIF)
S4 Fig. Superposition of the RNA-bound and the RNA-free crystal structures of HuR
RRM1/2 suggests a large (41 Å) interdomain swinging motion of RRM2 upon RNA-bind-
ing. Our NMR data does not detect this large interdomain motion of RRM1 and RRM2 upon
RNA-binding. Crystal structures of (A) RNA-bound (PDB ID: 4ED5) and (B) RNA-free HuR
RRM1/2 (PDB ID: 4EGL). (C) Superposition of the (A) RNA-bound and the (B) RNA-free
forms of HuR RRM1/2. The structures are superimposed on the RRM1 domain. The structures
are colored as follows: RRM1 (green), the inter-domain linker region (yellow), RRM2
(orange), and RNA (blue).
(TIF)
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